“My LIFE gives me hope!”
November is Pulmonary Hypertension Awareness Month, and anticipation is growing at the Pulmonary Hypertension Association (PHA). Starting Nov. 1, PHA will launch a month-long awareness campaign called “PHaces of Hope,” which will focus on the faces of those who bravely fight pulmonary hypertension (PH), showing how PH can affect individuals of any age, everywhere.
Dr. Jeffrey Sager is the director of the Pulmonary Hypertension Care Center (PHCC) at Cottage Rehabilitation Hospital & Goleta Valley Cottage Hospital in Santa Barbara, Calif. He also serves on the Pulmonary Hypertension Association’s (PHA’s) Scientific Leadership Council. In this story, he discusses his work with pulmonary hypertension (PH) and his connection to PHA.
Medicare Open Enrollment has begun. Now through Dec. 7, 2019, individuals with health insurance through Medicare can make changes to their existing coverage. The Pulmonary Hypertension Association (PHA) offers guidelines for choosing Medicare coverage at https://PHAssociation.org/Patients/Insurance/Medicare/. On this page you will find helpful videos, and other resources to help with you better understand Medicare. One-on-one
“I’m working and raising my children. I’m currently writing a book and creating a blog, so that I can tell my full story. I’m so glad my children can see their mom LIVE with PH!” By CraShundra Richardson One Sunday in September 2015, I remember making dinner and then I wasn’t hungry enough to
The Pulmonary Hypertension Association’s (PHA’s) The Right Heart blog brings you a story about a patient that was diagnosed with pulmonary hypertension (PH) in October 2015 after realizing she had a family history of this disease. CraShundra Richardson started experiencing fatigue early on and went to her doctor. Her doctor recommended that she get
Dear PH Community, Here in Washington, D.C., autumn has arrived with some cooler weather and the first golden and orange leaves. Fall means that vacations are mostly over, and school is back in session. It also means that the complex process of open enrollment is almost upon us. The Pulmonary Hypertension Association (PHA) is
Trevyent®, a new treatment system that utilizes subcutaneous delivery of treprostinil for pulmonary arterial hypertension (PAH) patients, was submitted to the U.S. Food & Drug Administration (FDA) for approval. The FDA received a New Drug Application (NDA) by United Therapeutics Corporation in September for Trevyent, a disposable pump and skin patch system or PatchPump®
Kristine Ritenour, a pulmonary hypertension (PH) nurse coordinator at the Medical University of South Carolina, serves as the Pulmonary Hypertension Association (PHA) support group leader of the Lowcountry Charleston Support Group in Charleston, S.C. Kristine started leading a support group because she believes it’s important to give patients a place to connect and learn more